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Background: Late onset of radiation-induced haemorrhagic cystitis (RHC) after radiation therapy (RT)
for prostate cancer (PCa) may present or evolve severely, requiring hospitalization with invasive in-
terventions. In the present study, we have analysed the prevalence and risk factors associated with the
onset of RHC.
Methods: From January 2002 to May 2017, 1421 patients undertook RT for PCa as a primary, adjuvant, or
salvage treatment option. RHC presented in 5.6% (n ¼ 80) of the patients; the diagnosis was based on
clinical and endoscopic characteristics. Variables in observation included patients, tumours, and RT-
dosimetry characteristics. Patients with a previous history of bladder cancer were excluded. Univariate
(Student t/Chi square) and uni-/multivariate Cox regression analysis were performed; the events and
time-points were hospitalization and time-to-event, respectively.
Results: There were 80 patients with a mean age at RT of 70.1 years (SD 6.4), mean time lag to RHC of
43.9 months (SD 37.5). Median Emergency attendance was two and three times for patients without/with
hospitalization, respectively. There were in total 64 admissions with invasive treatment required in 26/36
(72.2%) of the patients hospitalised, including transurethral fulguration in 22 and radical cystectomy in 5.
Patients at higher risk of hospitalization were those undertaking antiplatelet/anticoagulant treatment
(HR:3.30; CI 95%:1.53e3.30; p ¼ 0.002) and those treated with salvage RT with higher bladder volume
receiving >70 Gy (bladder V70) (HR:1.03; CI 95%:1.01e1.05; p ¼ 0.027). At receiving operating charac-
teristic analysis, the cutoff for bladder V70 was 29%.
Conclusion: Nearly half of patients presenting RHC may require invasive treatment including cys-
tectomy. Risk factors associated with hospitalization are patients undertaking antiplatelet/coagulant
treatment and bladder V70 > 29% in salvage RT patients.
© 2020 Asian Pacific Prostate Society. Publishing services by Elsevier B.V. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).5, Barcelona, Spain.
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Radiotherapy (RT) is one of the treatment options available for
patients affected by prostate cancer (PCa); it is indicated for pri-
mary treatment, in an adjuvant regime, or in the setting of salvage
treatment after biochemical recurrence postradical prostatectomy
[1,2]. However, adverse events may occur acutely or during follow-
up due to toxic effects on the gastrointestinal (GI) and/or of the




Patients with diagnosis of prostate cancer
Patients treated with radiotherapy for primary tumour, or in adjuvant/salvage
regime after radical prostatectomy
Patients with visible/gross haematuria and endoscopic characteristics
of radiation-induced haemorrhagic cystitis (RHC) according to predefined
criteria [8]
Exclusion criteria
Patients with past medical history of bladder cancer
Diagnosis of bladder cancer within 6 months from the diagnosis of RHC
Suspicious or positive urine cytology
Patients with radiation therapy (RT) for other diseases
Patients presenting RHC with RT performed in other centres
F. Sanguedolce et al. / Radiation-induced hemorrhagic cystitis 49Radiation-induced cystitis (RC) includes bladder toxicities of
Grade 2 according to the Radiation Therapy Oncology
Group (RTOG) classification and refers to different degrees of low
urinary tract symptoms (LUTS) and haematuria [3].
Incidences of RC reported in literature range between 2% and
59% of patients treated for pelvic cancers: this wide range may be
due to the heterogeneity of definitions adopted in literature, which
may include acute and/or late toxicities, or even all types of RC
(including bladder loss capacity, LUTS, etc.) or just the subgroup of
the radiation-induced haemorrhagic cystitis (RHC) [4,5].
The RHC is among the most threatening RT complications as it
may account for a significant proportion of urological emergency
(A&E) admissions and/or hospitalization [6]. Treatment options
involve a variety of approaches depending on the severity of the
haematuria, including conservative managements like hydration
and/or bladder irrigation up to the endoscopic fulguration or even
cystectomy.
RHC can develop from 6 months to as long as 20 years after RT,
with a mean latent time of 35 months [7].
In the present study, we report the prevalence of RHC in a sin-
gle-centre cohort of patients who received RT for PCa (either as
primary or as adjuvant/salvage treatment), the types of manage-
ment undertaken, and the risk factors associated with
hospitalization.
2. Patients and methods
A cohort of 1421 patients that underwent RT for PCa in a single
center was retrospectively analysed from January
2002dcorresponding to the local establishment of the three-
dimensional conformal external beam RT (EBRT) with high en-
ergy linear accelerator dto May 2017. We included patients that
received RT as a primary treatment, in adjuvant regime or as a
salvage option in case of biochemical recurrence after radical
prostatectomy.
The diagnosis of RHC was based on the combination of visible
haematuria requiring admission to A&E not related to urinary tract
infection, and of cystoscopic findings; diagnostic criteria on this
latter regard included the absence of bladder lesions and/or stones
as well as the presence of pale mucosa, diffused telangiectasia and/
or petechiae, or even ulcerations, as described and standardised by
Fajardo in 1978 [8]. Moreover, urine cytology was always per-
formed to further rule out bladder urothelial carcinoma in situ
(CIS): in case of suspicious or positive findings, random bladder
biopsies and CT scan were performed.
Patients with a history of bladder cancer (BCa) were excluded, as
well as patients diagnosed of BCa within 6 months from the diag-
nosis of RHC (see Table 1 with inclusion/exclusion criteria). In pa-
tients with later diagnosis of BCa, the RHC follow-up was
discontinued at the date of the latest control prior to the BCa
diagnosis. For the remainder of the patients, follow-upwas counted
until the latest outpatient clinic visit or the date of death.
The primary endpoint consisted of the identification of factors
associated with Grade 3 RTOG bladder toxicity requiring hospi-
talization; secondary endpoint included a descriptive narration of
the treatments undertaken as well as their efficacy and morbidity.
Events and time-points consisted of hospitalization (yes vs. no) and
time-to-event, respectively. Patients not requiring hospitalization
were labeled as Group 1, those who needed hospital admission
were identified as Group 2.
Among the variables taken into account for analysis, there were
patient's comorbidities, antiplatelet/coagulant therapy, age at the
time of RT, indication of RT, fraction dose, percentage bladder vol-
ume receiving 70 Gy (bladder V70), mean bladder dose, acute
bladder toxicity during RT, number of emergency room attendance,number of hospital admissions, and treatment for RHC. The bladder
V70 parameter was chosen according to the findings of Schaake
et al and measured on the outer layer of the bladder wall [9].
For patients requiring hospitalization, continuous bladder irri-
gation, transurethral fulguration (TUF) of the bladder and cys-
tectomy were the treatment modalities adopted according to the
gravity and/or persistency of haematuria. TUF was performed with
low-energy monopolar setting (50 Hz) in the bleeding spots and
areas with telangiectasia [10]. Bladder instillations with hyaluronic
acid (HA) and hyperbaric oxygen therapy (HBOT) were planned
after haematuria remission (either with or without hospitalization)
to prevent recurrence, in an ambulatory regime.
Statistical analysis included descriptive statistics of the variables
in observation (standard deviation, median and interquartile
rangedIQRd25e75), univariate (Student t and Chi square), and
uni-/multivariate Cox regression analysis performed to assess risk
factors for hospitalization. Relevant cutoff values were calculated
by means of the Receiving Operating Characteristic (ROC) curve
analysis. Tests significance level was set at P values <0.05 (R Sta-
tistical Software).3. Results
After screening for the inclusion/exclusion criteria, a total of 80
PCa patients treated with RT presented RHC in the period in
observation, corresponding to the 5.6% of the overall cohort of RT
patients, and were included in the analysis. Half of the patients
undertook primary RT, and another half received salvage RT; no
patient in the final cohort underwent adjuvant RT.
The median follow-up of the patients was 36 months (IQR:
18.75e49.25). Most of the patients harbored intermediate (40%)
and high risk (33.75%) PCa according to the National Comprehen-
sive Cancer Network risk stratification [2]. In 97.5% of the cases, a
three-dimensional conformal RT was undertaken, with a median
fractionation of 1.8 Gy. The demographics of patients are detailed in
Table 2.
Out of 80 patients (55%; Group 1), 44 attended A&E at our
institution because of intermittent haematuria that remitted either
spontaneously with hydration or temporal catheterization with/
without bladder wash-out; median times of A&E attendance was 2
(IQR 1e4).
Only one patient in this subgroup of patients received HA in-
stillations, completing the induction course (1-weekly 6) with no
maintenance instillation performed.
Hospitalization was needed in the remainder 36 patients (45%;
Group 2), due to persisting haematuria requiring continuous
bladder irrigation and/or urgent endoscopic bladder clot washout
in the theater; median A&E attendance prior to hospitalizationwas





Group 1 (no hospital admission)
N ¼ 44
Group 2 (hospital admission)
N ¼ 36
P
Age at the RT (SD) 70.1 (6.4) 68.8 (6.5) 71.4 (6.1) 0.067
Diabetes mellitus (SD) 24 (30%) 11 (25%) 13 (36.1%) 0.646
Hypertension (SD) 53 (66.25%) 25 (56.8%) 28 (77.7%) 0.354
Anticoagulant or/and antiplatelet treatment 20 (25%) 5 (11.3%) 15 (41.6%) 0.012
NCCN prostate cancer risk group
- Very low risk 4 0 4 0.011
- Low risk 4 0 4
- Intermediate risk 32 20 12
- High risk 27 15 12
- Very high risk 10 8 2
- N/A 3 1 2
Indication for RT
- Primary 40 (50%) 18 (40.9%) 22 (61.1%) 0.150
- Adjuvant 0 0 0
- Salvage 40 (50%) 26 (59.1%) 14 (38.9%)
Type of RT
- Brachytherapy 1 0 1 0.45
- 3D CRT 1 43 35
- IMRT/IGMT 1 1 0
Fractionation-Gy (median) 1.8 1.8 1.8 0.972
RT of lymph nodes
 Yes 68 (85.0%) 38 (86.3%) 30 (83.3%) 0.175
 No 12 (15.0%) 6 (13.7%) 6 (16.7%)
GU acute toxicities (during RT)
- Visible/gross haematuria 1 (1.25%) 1 (2.7%) 0 (0%) 0.980
- Acute urine retention 1 (1.25%) 1 (2.7%) 0 (0%) 0.980
- Urinary tract infection 1 (1.25%) 1 (2.7%) 0 (0%) 0.980
- Dysuria 77 (96.25%) 41 (93.2%) 36 (100.0%) 0.714
Hormonal treatment 38 (47/5%) 19 (43.18%) 19 (52.7%) 0.928
Mean bladder dose (Gy) 60.5 (9.7) 61.4 (9.3) 59.6 (10.1) 0.432
Mean bladder V70 (%) 35.0 (27.8) 32.4 (26.8) 37.8 (28.8) 0.395
Time from RT to cystitis, months 43.9 (37.5) 42.3 (35.1) 45.7 (40.3) 0.682
RT, radiotherapy; SD, standard deviation; NCCN, National Comprehensive Cancer Network; 3D CRT, three-dimensional conformal radiotherapy; IMRT, intensity-modulated
radiotherapy; IGRT, imaging-guided radiotherapy; Gy, gray.
Prostate International 9 (2021) 48e5350and/or catheter tamponade for clots. Nearly half of these patients
(n ¼ 15/36; 41.66%) were hospitalised for more than once (IQR:
2e3). There were in total 64 hospital admissions, with 26 patients
(72.2% of Group 2) requiring invasive procedures in theatre and
with a mean hospital stay of 7 days (IQR: 4e11.75).
The treatment modalities undertaken are summarised in
Table 3. All patients were admitted with continuous bladder irri-
gations. TUF was commonly performed (n ¼ 22, 61.1%) with six and
two patients needing a second and a third TUF during the follow-
up, respectively. Ambulatory consolidative treatment was per-
formed in seven patients, six with HA instillations (median of 6
instillations), and one with HBOT. Only one of these patients pro-
gressed to refractory haematuria requiring cystectomy.
Blood transfusions were needed in 38.9% of Group 2 patients
with a median of 2 units transfused per patient (IQR: 2e5.5),
including all the admissions recorded.Table 3
Treatments undertaken in patients hospitalised.
Treatment N (%)
Bladder catheter þ washout 36/36 (100%)
TUF (þ second or third repeated TUF) 22/36 (61.1%) (þ6 þ 2)
Cystectomy 6a)/36 (16.6)
Blood transfusion 14/36 (38.9)
Consolidation treatment:
-HA bladder instillation 6/36 (16.6)
-HBOT 1/36 (2.7)
TUF, transurethral fulguration; HA, hyaluronic acid; HBOT, hyperbaric oxygen
therapy.
a) Includes one patient undertaking radical cystectomy for bladder cancer.Bladder urothelial cancer was detected in five patients during
the follow-up, after >6months from the diagnosis of RHC, with one
patient requiring radical cystectomy in the follow-up.
Radical cystectomy was also performed in further five RHC pa-
tients as a result of severe haematuria not responding to conser-
vative management (n ¼ 3) and of remittent RHC in a low-volume
bladder capacity associated to severe dysuria (n ¼ 1). All these
patients experienced a range of complication: two patients expe-
rienced Grade II (ileus requiring parenteral nutrition), two patients
had a Grade IIIb (ileal anastomosis leakage at 8 days post-op, and
ileal conduit fistula at 60 days post-op, both requiring surgical in-
terventions), and one developed a Grade IV (sepsis requiring
intensive care unit management) according to the modified Clav-
ieneDindo classification for postoperative complications [11]. One
of these patients eventually died 6 months after surgery for the
complications of pseudomembranous colitis that required total
colectomy.
At univariate analysis, clinical variables associated to the
admission to the hospital were time from RT to diagnosis of HRC
(HR:0.91; CI 95%:0.88e0.98; p ¼ 0.041) and anticoagulant treat-
ment (HR:2.89; CI 95%:1.40e3.38; p ¼ 0.030).
At multivariate Cox regression analysis (see Table 4), anticoag-
ulant/antiplatelet treatment and bladder V70 in the setting of
salvage RT patients were found to be the only variables significantly
associated to the events (HR:3.30; CI 95%:1.53e3.30; p ¼ 0.002,
HR:1.03; CI 95%:1.01e1.05; p ¼ 0.027, respectively). At ROC, the
cutoff value for the bladder V70 was 29%.
A sensitive analysis was performed by removing from the Cox
regression analysis patients with BCa detected in follow-up, and no
difference of the outcomes was observed.
Table 4
Multivariate Cox model analysis.
Adjusted model p
HR CI 95%
Time from RT to RHC 0.96 0.92e1.01 0.072
Antiplatelet/anticoagulant treatment 10.9 4.23e10-7 <0.001
Age at the onset of RHC 1.09 0.98e1.22 0.110
Bladder v70 in salvage RT patients 1.03 1.01e1.05 0.027
Type of RT (primary vs. salvage) 1.15 0.55e1.35 0.650
RT, radiotherapy; RHC, radiation-induced haemorrhagic cystitis.
F. Sanguedolce et al. / Radiation-induced hemorrhagic cystitis 514. Discussion
RHC has been shown to be a serious late adverse event of RT:
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ported a 7.2% of RT patients admitted from A&E for RT complica-
tions (90% after prostate RT), with RHC accounting for more than
half of the cases; similarly, two-thirds of the RT complications
required surgical intervention, with bladder TUF for RHC being the
most common one [6]. Our study is in line with these latter figures,
with a prevalence of 5.6% of prostate RT patients experiencing HRC,
and a median of three attendances per patient to our A&E; nearly
half of these patients required hospitalization, requiring a variety of
low urinary tract manipulations.
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Prostate International 9 (2021) 48e5352To identify patients at higher risk for hospital admission and
invasive management, we looked at factors associated with hos-
pital admission, finding at multivariate analysis the anticoagulant/
antiplatelet therapy and bladder V70 in the subgroup of salvage RT
patients as factors significantly associated to the events. This latter
finding is consistent with a recent publication regarding a cohort of
salvage RT patients after radical prostatectomy biochemical failure
where the relevant dosimetric parameter was associated with a
significantly higher risk to develop a Grade >2 late genitourinary
toxicity (HR 1.05, CI 95%: 1.02e1.08. p¼ 0.001) [12]. The association
of anticoagulant/antiplatelet therapy with a severe degree of RHC is
very much intuitive as it is likely the result of the induced bleeding
diathesis on an affected urothelium. On the other hand, the role of
bladder V70 in patients receiving salvage RT after radical prosta-
tectomy could bemultifactorial: from one side, the treatment of the
surgical field expose to a direct effect of the radiations to the
bladder; moreover, it must be noted that some of these patients
may suffer a certain degree of incontinence (for surgery or aging)
which might prevent them in keeping a full bladder during the RT
sessions being this latter described as a protector to GU and GI
toxicity [13].
While bladder washout and TUF are established first-line
treatments, HA and HBOT are treatment options usually adopted
as consolidation therapy to prevent the recurrence of haematuria
after the resolution of an acute episode [14] [15].
In our series, all patients were initially managed with bladder
washout (either at A&E or as inpatients) and TUF was necessary for
nearly two-thirds of patients requiring hospitalization, with six of
them undertaking multiple TUF and four patients (plus further two
patients with metachronous BCa) ending up with radical
cystectomy.
Eight patients, one of the non-hospitalised group and seven of
the hospitalised group, received a consolidation therapy, with only
one nonresponding to the treatment and requiring finally a radical
cystectomy. Most of these patients received HA (n¼ 7) as HBOTwas
logistically difficult to get access to. Although HBOT has been more
extensively investigated, the intravesical instillation of HA (þ/
chondroitin sulfatedCS-) in the setting of pelvic radiation cystitis is
a more recent therapeutic option: Gacci et al found a significant
improvement in patients who developed severe LUTS after prostate
RT in a cohort of 80 patients undergoing intravesical instillation of
HA þ CS [16]. In a head-to-head comparison, 36 RHC patients were
randomly assigned to receive either HBOTor HA, and no differences
in efficacy were recorded at all the time-points, suggesting that
both therapies are equally effective [17].
Cystoprostatectomy is the last resort for RHC refractory to all
the conservatory treatment options as it is strongly associated
with severe comorbidities and with a higher risk of intra-/post-
operative mortality: in our cohort, three out of five patients (60%)
undergoing cystectomy with final histology of actinic cystitis
experienced severe complications (ClavieneDindo Grade 3), and
one patient died as a result of later complications of the surgery at
6-month post-op. These results are consistent with the outcomes
published by Linder et al with 42% of severe complication rate and
16% of mortality rate, respectively, within 90 days from surgery
[18].
Our findings may help practitioners in identifying those RHC
patients at higher risk to eventually prompt prophylactic measures.
An emerging option is the glycosaminoglycan replenishment
therapy for patients experiencing acute bladder toxicity during
pelvic RT: one pilot study showed a benefit of the instillation of
chondroitin sulfate in a small cohort of 20 female symptomatic
patients receiving pelvic RT; a further randomised controlled trial
with prophylactic HA þ CS instillation in PCa patients receiving RT
is ongoing [19] [20].AS a result of our outcomes, we have established a protocol to
undertake appropriate actions in an attempt to reduce the risk of
progression of RHC after the first presentation of haematuria; we
strongly believe that its application can be generalised although
further studies might be needed (see Fig. 1).
Our study has some limitations: it is a retrospective study, and
relevant confounding factors (like selection bias) may be present.
We have not weighted our findings against the rest of the RT cohort
during the study period; however, the study design intentionally
involved only the patients with diagnosis of RHC as the primary
endpoint consisted in identifying factors associated with bladder
toxicity requiring hospitalisation and invasive treatment.
Also, wewere unable tomeasure how the patients' quality of life
was affected, as no patients’ reported outcomes tools were used
due the retrospective nature of the study; however, it is reasonable
to estimate that with several admissions to A&E, eventual
hospitalization ± the relevant invasive manoeuvres, patients with
RHC have a severely impaired quality of life.
Finally, we believe that on the basis of this study's outcomes
future trials could be undertakenwith better patients' selection and
appropriate planning of treatment strategies.
5. Conclusion
RHC is a fearsome late complication of prostate RT even in the
modern era of RT. Antiplatelet/anticoagulant therapy and bladder
V70 > 29% are the factors associated with the need of patients’
hospitalization. A variety of treatment options are available,
although they are associated to an impairment of quality of life and
severe risk of complications. Prophylactic measures in patients at
higher risks of severe RHC may prevent the progression of the









RTOG Radiation Therapy Oncology Group
RHC radiation-induced haemorrhagic cystitis
A&E accident and emergency department
EBRT external beam radiotherapy
BCa bladder cancer
Bladder V70 percentage of bladder volume irradiated with 70 Gray
TUF transurethral fulguration
HA hyaluronic acid
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